The relevance of coagulation in cardiovascular disease: what do the biomarkers tell us?

Gordon Lowe; Ann Rumley

doi:10.1160/th14-03-0199

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2014; 112(05): 860-867
DOI: 10.1160/th14-03-0199

Theme Issue Article

Schattauer GmbH

The relevance of coagulation in cardiovascular disease: what do the biomarkers tell us?

Authors

Gordon Lowe

¹Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
Ann Rumley

¹Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK

Abstract

Summary

Several haemostatic factors have been associated with incident arterial cardiovascular disease in prospective studies and meta-analyses. Plasma fibrinogen shows a strong and consistent association with risk; however, this may reflect its inflammatory marker status, and causality remains to be proven. The common haemostatic gene polymorphisms for factor II, factor V and the von Willebrand factor: Factor VIII (non-O blood group) show significant associations with coronary heart disease (CHD) risk, consistent with potential causality. Increased D-dimer and t-PA antigen levels are associated with CHD risk, suggesting roles for coagulation activation and endothelial disturbance. There is little evidence for associations with CVD with other haemostatic factors.

Keywords

Arterial thrombosis - epidemiological studies - coagulation factors

Full Text

References

References
1 Macfarlane RG. Introduction. Br Med Bull 1977; 33: 183-185.
2 Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 1095: 1135-1143.
3 Lowe GDO. Can haematological tests predict cardiovascular risk ? The 2005 Kettle Lecture. Br J Haematol 2006; 133: 232-250.
4 Lowe GDO. Epidemiology of venous thromboembolism: the need for large (including prospective) studies and meta-analyses. J Thromb Haemost 2012; 10: 2186-2188.
5 Rosendaal FR. Etiology of venous thrombosis: the need for small original studires. J Thromb Haemst 2012; 10: 2191-2193.
6 Jespersen J, Bertina RM, Haverkate F. Laboraory testing in thrombosis – a manual. 2nd edn.. Dordrecht: Kluwer Academic Publishers; 1999
7 Willeit P, Thompson A, Aspelund T. et al. Haemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses. PLoS One 2013; 8: e55175.
8 Peters SA, Woodward MA, Rumley A. et al. Direct comparisons of three plasma fibrinogen assays wth the von Clauss assay in prediction of cardiovascular disease and all-causes mortality: the Scottish Heart Health Extended Cohort. Br J Haematol 2013; 162: 392-399.
9 Lewis MR, Callas PW, Jenny NS. et al. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Hae-most 2001; 86: 1495-1500.
10 Woodward M. Epidemiology. Study Design and Data Analysis. 2nd ed.. Boca Raton: Chapman and Hall / CRC Press; 1999
11 Lowe GD, Rumley A, Sweetnam PM. et al. Fibrin D-dimer, markers of coagulation activation and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 2001; 86: 822-827.
12 Stott DJ, Robertson M, Rumley A. et al. Activation of haemostasis and decline in cognitive function in older people. Aretrioscler Thromb Vasc Biol 2010; 30: 605-611.
13 Verhovsek M, Douketos J, Yi Q. et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008; 149: 481-490.
14 Tosetto A, Iorio A, Marcucci M. et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10: 1019-1025.
15 Emerging Risk Factors Collaboration. Kaptoge S, Angelantonio E, Pennells L. et al. C-reactive protein, fibrinogen and cardiovascular disease prediction. N Engl J Med 2012; 367: 1310-1320.
16 Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113: 2335-2362.
17 Woodward M, Tunstall-Pedoe H, Rumley A. et al. Does fibrinogen add to prediction of cardiovascular disease? Results from the Scottish Heart Heart Extended Cohort Study. Br J Haematol 2009; 146: 442-446.
18 Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and non-vascular mortality: an individual participant meta-analysis. J Am Med Assoc 2005; 294: 1799-1809.
19 Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparioson of C-reactive protein, fibrinogen, homocysteine, lipoprotain (a), and standard cholesterol screening as predictors for peripheral arterial disease. J Am Med Assoc 2001; 285: 2481-2485.
20 Tzoulaki I, Murray GD, Lee AJ. et al. Inflammatory, haemostatic and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J 2007; 28: 354-362.
21 Fibrinogen Studies Collaboration. Associations of plasma fibrinogen levels with established cardiovascular risk factors, inflammatory markers and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies. Am J Epidemiol 2007; 166: 867-879.
22 Danesh J, Collins R, Appleby P. et al. Associations of fibrinogen, C-reactive protein, albumin or leucocyte count with coronary heart disease: meta-analyses of prospective studies. J Am Med Assoc 1998; 279: 1477-1482.
23 Danesh J, Collins R, Peto R. et al. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 2000; 21: 515-520.
24 Lowe GDO. Ancrod in acute ischaemic stroke. Proc Roy Coll Phys Edin 2001; 31 (Suppl. 08) 20-24.
25 Hennerici MG, Kay R, Bogousslavsky J. et al. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet 2006; 368: 1871-1878.
26 Sabater-Lleal M, Huang J, Chasman D. et al. Multiethnic meta-analysis of genome-wide association studies in > 100,000 subjects identifies 23 fibrinogen-associated loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease. Circulation 2013; 128: 1310-1324.
27 Machlus KR, Cardenas JC, Church FC. et al. Causal relationship between hyper-fibrinogenemia, thrombosis and resistance to thrombolysis in mice. Blood 2011; 117: 4953-4963.
28 Ariens RAS. Fibrin(ogen) and thrombotic disease. J Thromb Haemost 2013; 11 (Suppl. 01) 294-305.
29 Kaptoge S, Seshasai SR, Gao P. et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analyses. Eur Heart J. 2013 Epub ahead of print.
30 Paterson CC, Smith AE, Yarnell JW. et al. The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the Caerphilly Study. Atherosclerosis 2010; 209: 551-557.
31 Sarwar N, Butterworth AS, Freitag DF. et al. IL6R Genetics Consotium., Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379: 1205-1213.
32 CRP CHD Genetics Consortium. Association between C-reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. Br Med J 2011; 342: d548.
33 Lowe G, Woodward M, Hillis G. et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes mellitus and cardiovascular disease or risk factors: the ADVANCE Study. Diabetes. 2014 63.
34 Yamagishi K, Aleksic N, Hannan PJ. et al. Coagulation factors II, V, IX, X. XI, XII, plasminogen and alpha2antiplasmin and risk of coronary heart disease. J Atheroscler Thromb 2010; 17: 402-409.
35 Juul K, Tybjaerg-Hansen A, Schnohr P. et al. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med 2004; 140: 330-347.
36 Weischer M, Juul K, Zacho J. et al. Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population. Atherosclerosis 2010; 208: 480-483.
37 Emmerich J, Rosendaal FR, Cattaneo M. et al. Combined effect of factor V Leiden and prothrombin 20120A on the risk of venous thromboembolism. Thromb Haemost 2001; 86: 809-816.
38 Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20120A, and methylenetetrafolatereductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146: 948-957.
39 Ye Z, Liu EHC, Higgins JPT. et al. Seven haemostatic gene polymorphisms in coronary heart disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-658.
40 Smith A, Patterson C, Yarnell J. et al. Which haemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and stroke ? The Caerphilly Study. Circulation 2005; 112: 3080-3087.
41 Van der Bom JG, Bots ML, Haverkate F. et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Me 1996; 125: 265-269.
42 Empana JP, Canoui-Poitrine F, Luc G. et al. Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study. Eur Heart J 2008; 29: 1966-1974.
43 Ten Cate H. Tissue factor-driven thrombin generation and inflammation in atherosclerosis. Thromb Res 2012; 129 (Suppl. 02) S38-40.
44 Smith NL, Huffman JE, Strachan DP. et al. Genetic predictors of fibrin D-dimer levels in healthy adults. Circulation 2011; 123: 1864-1872.
45 Meade TW, De Stavola B. Long-term effects of haemostatic variables on fatal coronary heart disease: 30 year results from the first prospective Northwick Park Heart Study (NPHS-1). J Thromb Haemost 2007; 5: 461-471.
46 Cooper JA, Miller GJ, Bauer KA. et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000; 102: 2816-2822.
47 Tzoulaki I, Murray GD, Lee AJ. et al. Relative value of inflammatory, hemostatic and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007; 115: 2119-2127.
48 Zakai NA, Katz R, Jenny NS. et al. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly; the Cardiovascular Health Study. J Thromb Haemost 2007; 5: 1128-1135.
49 Folsom AR, Wu KK, Rosamond WD. et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-1108.
50 Junker R, Heinrich J, Schulte H. et al. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997; 17: 1539-1544.
51 Lowe GD, Rumley A, McMahon A. et al. for the West of Scotland Coronary Prevention Study Group. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24: 1529-1534.
52 Folsom A, Rosamond W, Shahar E. et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation 1999; 100: 736-742.
53 Rudnicka AR, Mt-Isa S, Meade TW. Associations of plasma fibrinogen and factor VII clotting activity with coronary heart disease and stroke: prospective cohort study from the screening phase of the Thrombosis Prevention Trial. J Thromb Haemost 2006; 4: 2405-10.
54 Meade TW, Stirling Y. The Northwick Park Heart Studies: contrasts between the two Factor VII assays used. J Thromb Haemost 2012; 10: 482-484.
55 Bongers TN, de Maat MP, van Goor ML. et al. High von Willebrand factor levels increase the risk of first ischaemic stroke: influence of ADAMTS13. inflammation, and genetic variability. Stroke 2006; 37: 2672-2677.
56 Wannamethee SG, Whincup PH, Lennon L. et al. Fibrin D-dimer, tissue-type plasminogen activator, von Willebrand factor and risk of incident stroke in older men. Stroke 2012; 43: 1206-1211.
57 Rumley A, Lowe GDO, Sweetnam PM. et al. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Study. Br J Haematol. 1999; 105: 110-116.
58 Meade TW, Mellows S, Brozovic M. et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-537.
59 Meade TW, Cooper JC, Stirling Y. et al. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol. 1994; 88: 601-607.
60 Jenkins PV, Rawley O, Smith OP. et al. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 2012; 157: 653-663.
61 Sramek A, Kriek MD, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003; 362: 351-354.
62 Tuinenburg A, Mauser-Bunschoten EP, Verhaar MC. et al. Cardiovascular disease in patients with hemophilia. J Thromb Haemost 2009; 7: 247-254.
63 Sanders YV, Eikelboom J, de Wee EM. et al. Reduced prevalence of aretrial thrombosis in von Willebrand disease. J Thromb Haemost 2013; 11: 845-854.
64 Sramek A, Reiber JHC, Gerrits WBJ. et al. Decreased coagulability has no clinically relevant effect on atherogenesis. Observations in individuals with a hereditary bleeding tendency. Circulation 2001; 104: 762-767.
65 Wu O, Bayoumi N, Vickers MA. et al. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 62-69.
66 Dentali F, Sironi AP, Ageno W. et al. Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. Semin Thromb Haemost 2012; 38: 535-548.
67 Dentali F, Sironi AP, Ageno W. et al. ABO blood group and vascular disease: an update. Semin Thromb Haemost 2014; 40: 49-59.
68 Van Loon JE, Karousi M, Leebeck FW. et al. Von Willebrand factor plasma levels, genetic variations and coronary heart disease in an older population?. J Thromb Haemost 2012; 10: 1262-1269.
69 Van Schie MC, Wieberdink RE, Koudstaal PJ. et al. Genetic determinants of von Willebrand factor plasma levels and the risk of stroke: the Rotterdam Study. J Thromb Haemost 2012; 10: 550-556.
70 Rumley A, Lowe G, Stott D. et al. Coagulation activation markers are associated with cardiovascular events and death in the elderly at risk: PROSPER study cohort. J Thromb Haemost. 2009 Suppl 2. Abstract OC-WE-033.
71 Algra TB, van de Graaf Y, Helmerhorst F. et al. Procoagulant factors and the risk of myocardial infarction in young women. Eur J Haematol 2006; 77: 67-73.
72 Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men : opposite and synergistic effects of factors XI and XII. Blood 2006; 108: 4045-4051.
73 Berliner JI, Rybicki AC, Kaplan RC. et al. Elevated levels of Factor XI are associated with cardiovascular disease in women. Thromb Res 2002; 107: 55-60.
74 Merlo C, Wullemin WA, Redondo M. et al. Elevated levels of plasma prekallik-rein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis 2002; 161: 261-267.
75 Santamaria A, Martinez-Rubio A, Mateo J. et al. Homozygosity of the T allele of the 46C-T polymorphism in the F12 gene is a risk factor for acute coronary artery disease in the Spanish population. Haematologica 2004; 89: 878-894.
76 Santamaria A, Mateo J, Tirado I. et al. Homozygosity of the T allele of the 46C-T polymorphism in the F12 gene is a risk factor foie ischemic stroke in the Spanish population. Stroke 2004; 35: 1975-1799.
77 Tang W, Schweinbacher C, Lopez L. et al. Genetic associations for activated partial thromboplastin time and prothrombin time, their gene expression profiles, and risk of coronary artery disease. Am J Hum Genet 2012; 81: 152-162.
78 Voko Z, Bereczky Z, Katona E. et al. Factor XIII Val 34 Leu protects against caoronary artery disease. A meta-analysis. Thromb Haemost 2007; 97: 458-463.
79 Wells PS, Anderson JL, Scarvelis DK. et al. Factor XIII Val 34 Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. Am J Epidemiol 2006; 164: 101-109.
80 Soare AM, Popa C. Deficiencies of protein C, S and antithrombin and activated protein C resistance – their involvement in the occurrence of arterial thrombosis. J Med Life 2010; 3: 412-415.
81 Lowe GDO. Fibrin D-dimer and cardiovascular risk. Semin Vasc Med 2005; 5: 387-398.
82 Kleinegris MC, ten Cate H, ten Cate-Hoek AJ. D-dimer as a marker for cardiovascular + arterial thrombotic events in patients with peripheral arterial disease. A systematic review. Thromb Haemost 2013; 110: 233-243.
83 McCallum PK, Rudnicka A, Rumley A. et al. Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarction. Br J Haematol 2004; 127: 448-450.
84 Miller GJ, Ireland H, Cooper J. et al. Relationship between markers of activated coagulation, their correlation with inflammation, and their association with risk for coronary heart disease (NPHS II). J Thromb Haemost 2008; 6: 259-268.
85 Siegerink B, Govers-Riemslag JW, Rosendaal FR. et al. Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study. Circulation 2010; 122: 1854-1861.
86 Govers-Riemslag JW, Smid M, Cooper JA. et al. The plasma kallikrein-kinin system and risk of cardiovascular disease in men. J Thromb Haemost 2007; 5: 1896-1903.
87 Lowe GDO, Danesh J, Lewington S. et al. Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2004; 25: 252-259.
88 Meade TW, Ruddock V, Stirling Y. et al. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
89 Meade TW, Cooper JA, Miller GJ. Platelet counts and aggregation measures in the incidence of ischaemic heart disease (IHD). Thromb Haemost 1997; 78: 926-929.
90 Lowe GDO, Rumley A, Norrie J. et al on behalf of the West of Scotland Coronary Prevention Group. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study. Thromb Haemost 2000; 84: 553-558.
91 Elwood PC, Beswick A, Pickering J. et al. Platelet tests in the prediction of myocardial infarction and ischaemic stroke: evidence from the Caerphilly Prospective Study. Br J Haematol 2001; 113: 514-520.
92 Van der Bom JG, Heckbert SR, Lumley T. et al. Platelet count and the risk for thrombosis and death in the elderly. J Thromb Haemost 2009; 7: 399-405.
93 Chu SG, Becker RC, Berger PB. et al. Mean platelet volume as a predictor of cardiovascular risk: a meta-analysis. J Thromb Haemost. 2001 5. (Suppl 2): Abstract AS-TH-033.